atai Life Sciences announced that Anne Johnson, the Company?s interim Chief Financial Officer since October 2023 and Chief Accounting Officer since August 2022, has been named Chief Financial Officer (CFO). Anne succeeds Stephen Bardin as the Company?s CFO while Stephen will continue in an advisory role until March 31, 2024 to support the transition. Anne brings almost 20 years of biotechnology and pharmaceutical experience.

She previously served in senior leadership roles at Aruvant Sciences, Inc., a Roivant company; Chimerix Inc.; PPD; and Xanodyne Pharmaceuticals. Anne received her Bachelor of Science in Accounting from the University of North Carolina Wilmington and is a Certified Public Accountant and Chartered Global Management Accountant.